- Home
- ELWS vs XBIO Comparison
ELWS vs XBIO Comparison
Compare ELWS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- XBIO
- Stock Information
- Founded
- ELWS 2018
- XBIO N/A
- Country
- ELWS Japan
- XBIO United States
- Employees
- ELWS N/A
- XBIO N/A
- Industry
- ELWS
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- XBIO Health Care
- Exchange
- ELWS Nasdaq
- XBIO Nasdaq
- Market Cap
- ELWS 6.2M
- XBIO 6.3M
- IPO Year
- ELWS 2023
- XBIO N/A
- Fundamental
- Price
- ELWS $2.57
- XBIO $4.03
- Analyst Decision
- ELWS
- XBIO Hold
- Analyst Count
- ELWS 0
- XBIO 1
- Target Price
- ELWS N/A
- XBIO N/A
- AVG Volume (30 Days)
- ELWS 15.5K
- XBIO 4.8K
- Earning Date
- ELWS 12-31-2024
- XBIO 03-20-2025
- Dividend Yield
- ELWS N/A
- XBIO N/A
- EPS Growth
- ELWS N/A
- XBIO N/A
- EPS
- ELWS N/A
- XBIO N/A
- Revenue
- ELWS $1,139,113.00
- XBIO $2,523,427.00
- Revenue This Year
- ELWS N/A
- XBIO N/A
- Revenue Next Year
- ELWS N/A
- XBIO N/A
- P/E Ratio
- ELWS N/A
- XBIO N/A
- Revenue Growth
- ELWS 285.14
- XBIO 7.15
- 52 Week Low
- ELWS $1.04
- XBIO $2.78
- 52 Week High
- ELWS $8.68
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ELWS 38.57
- XBIO 45.61
- Support Level
- ELWS $2.75
- XBIO $3.91
- Resistance Level
- ELWS $2.92
- XBIO $4.24
- Average True Range (ATR)
- ELWS 0.23
- XBIO 0.17
- MACD
- ELWS -0.06
- XBIO -0.01
- Stochastic Oscillator
- ELWS 2.09
- XBIO 28.93
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.